NYSE MKT:	'RNN'	Market Capitalization:	$52 million
Recent Price (8/9/17):	$ 1.82	Shares Outstanding (6/30/17):	28.5 million
52-week Price Range:	$ 1.30 – $7.10	Burn Rate (per quarter):	$4 million
Avg Daily Volume (3m):	350,000	Cash (6/30/17):	$26.8 million

Analyst Coverage: ***FBR & Co.,*** Vernon Bernardino; ***H. C. Wainwright & Co.,*** Joe Pantginis; ***Laidlaw & Company Ltd,*** Yale Jen, Ph.D.; ***IFS Securities***, David Bouchey, Ph.D.

HEADQUARTERS

15245 Shady Grove Rd, Suite 455
Rockville, MD 20850
www.rexahn.com

MANAGEMENT TEAM

Peter D. Suzdak, Ph.D. — Chief Executive Officer — suzdakp@rexahn.com
Ely Benaim, MD — Chief Medical Officer — benaime@rexahn.com
Ted Jeong, D. Mgt. — Chief Financial Officer — ted@rexahn.com
Lisa Nolan, Ph.D. — Chief Business Officer — nolanl@rexahn.com

Business:

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, best-in-class **targeted therapeutics** for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next generation cancer therapies that specifically **target cancer cells** leading to **increased efficacy** while **minimizing side effects** traditionally associated with cancer treatment.

Investment Highlights:

- **Deep Oncology Pipeline with 3 Novel Programs Advancing in Clinical Development**

Rexahn has a diversified oncology pipeline that includes 3 novel potentially best-in-class, or first-in-class, anti-cancer agents advancing in clinical development with **Phase IIa** clinical data available from all three programs during 2017.



* Company estimates for 2025 based on forecasted patient numbers and pricing for new medications from DataMonitor and GlobalData (June 2016)

- **RX-3117 Showed Efficacy in Hardest to Treat Patients in a Phase IIa Clinical Trial in Pancreatic Cancer and Bladder Cancer Patients**

In a **Phase IIa** clinical trial, in pancreatic cancer patients that have failed 3 or more prior cancer therapies, 20% of patients treated with RX-3117 exhibited progression free survival (PFS) of greater than 5.6 months. There are no approved treatments for pancreatic cancer patients who have failed two or more prior therapies. Also in a separate **Phase IIa** clinical trial in metastatic bladder cancer who had failed 3 or more prior therapies, RX-3117 increased PFS to 6 months in 20% of the patients.

- **Phase IIa Clinical Trial in Triple Negative Breast Cancer Initiated for Supinoxin™ Based on Preliminary Evidence of Single Agent Activity**

Rexahn recently presented **Phase I** clinical trial data demonstrating single agent activity of Supinoxin with evidence of stable disease in patients with breast, neuroendocrine and colorectal cancers. A **Phase IIa** clinical trial in patients with triple negative breast cancer was initiated in 1Q 2017 with an initial data readout in 4Q 2017.

- **Archexin® Shows Preliminary Evidence of Tumor Reduction in Metastatic Renal Cell Carcinoma Patients**

Initial data from a **Phase IIa** clinical trial of Archexin in metastatic renal cell carcinoma (mRCC) patients showed promising signals of clinical activity with dose- and time-dependent evidence of tumor reduction and stable disease. Data from the completed study will be available 4Q 2017.

- **Pursuing Corporate Partnership Opportunities to Maximize Shareholder Value**

Rexahn is continuing discussions with multiple oncology-focused pharmaceutical companies and seeks to maximize the potential value of its drug development programs in any partnering transactions.

RX-3117: 2 Phase IIa Clinical Trials

RX-3117 is an orally-administered next generation, cancer cell specific nucleoside agent that induces apoptotic cell death selectively in cancer cells. RX-3117 is currently in **Phase IIa** clinical trials in both metastatic pancreatic cancer and muscle invasive bladder cancer.

Phase IIa:

Metastatic pancreatic cancer: RX-3117 treatment produced progression free survival in 20% of the patients of greater than 5.6 months (with one patient having progression free survival of 7.2 months). These patients had already failed 3 or more prior cancer therapies. Current options for these patients are usually limited to palliative or best supportive care and these patients normally have an expected survival of less than 2 months. An additional 40 metastatic pancreatic cancer patients are now being enrolled into the study and this data will be available in 4Q 2017.

Metastatic bladder cancer: RX-3117 treatment produced progression free survival in 20% of the patients of greater than 6 months (ASCO 2017). These patients had already failed 3 or more prior cancer therapies and normally have a PFS of 2 months. Additional patient data will be presented in 3Q 2017

Development Strategy:

Pursue clinical development in pancreatic cancer patients who have failed two or more prior anti-cancer therapies - No drug is currently approved for this indication, thus RX-3117 may be a candidate for an accelerated approval. RX-3117 will also be developed as a first line treatment and in combination with Abraxane® for newly diagnosed patients who have had no prior chemotherapy.

Supinoxin™: Phase I Clinical Trial

Supinoxin™ is an orally-administered, highly-potent, first-in-class anti-cancer small molecule that blocks cancer cell growth through inhibition of phosphorylated p68 which is found predominantly in cancer cells.

Phase IIa:

A Phase IIa clinical study in triple negative breast cancer patients was initiated in 1Q 2017 with an interim data readout in 4Q 2017.

Archexin®: Phase IIa Clinical Trial

Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth and drug resistance.

Phase IIa:

Archexin® is in the middle of a Phase IIa clinical trial in patients with metastatic renal cell (kidney) cancer.



Clinical data from initial part of the trial showed early evidence of potential dose- and time-dependent tumor reduction. Patients experienced reductions in their tumors ranging up to 36%, and exhibited stable disease (data presented at ASCO 2016). While the study is still ongoing, enrollment has been slowed down by the approval of three new drugs for mRCC (Opdivo® (nivolumab), Cabometyx® (cabozantinib) and Tecentriq® (atezolizumab)). Patients are cycling through these newly approved drugs before enrolling in the current study. We will have an update on the clinical study in 4Q 2017.

	Upcoming 2017 Clinical Milestones	Timing
RX-3117	Clinical data from stage 2 of a **Phase IIa** clinical Proof-of-Concept trial in metastatic pancreatic cancer patients	4Q
	Interim clinical data from stage 1 of a **Phase IIa** clinical Proof-of-Concept trial in metastatic bladder cancer	✓
	Additional clinical data from stage 1 of a **Phase IIa** clinical Proof-of-Concept trial in metastatic bladder cancer	3Q
Supinoxin™	Complete ongoing **Phase I** dose escalation trial, determine recommended Phase IIa dose and initiate a **Phase IIa** proof-of concept trial in triple negative breast cancer	✓
	Report interim data from stage 1 of a **Phase IIa** proof-of-concept clinical trial in triple negative breast cancer	4Q
Archexin®	Initial data readout from Archexin® **Phase IIa** clinical proof-of-concept trial in metastatic renal cell carcinoma	4Q